• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. George Talks About New Data on Checkpoint Inhibitors

Article

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013. A number of abstracts will be presented on both single agent and combinations of checkpoint inhibitors. Specifically, there is a Phase I study from Memorial Sloan-Kettering and Yale demonstrating a depth of response with the combination of ipilimumab and nivolumab for the treatment of melanoma. Dr George notes that this trial demonstrates "just how robust immunotherapy can be."

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Alexandra M. Trevino, MD, Northwestern Medicine
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
David J. Maron, MD, FASPC, Stanford University School of Medicine
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Rebecca Chacko, MD.
Dr María Díez Campelo
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.